Insight Center: Podcasts

Integration of IP and Regulatory Exclusivity Strategies for Emerging Life Science Companies

Speakers: Raymond A. Miller and N. Nicole Stakleff


Podcast Categories: IP, Life Sciences

Raymond A. Miller and N. Nicole Stakleff, Pittsburgh attorneys in Pepper Hamilton’s Intellectual Property Practice, and Tom Petzinger, Executive Vice President of Business Development and Public Affairs of Knopp Neurosciences Inc., identify the intellectual property and regulatory exclusivity strategies necessary for emerging life science companies to secure investments, strategic partnerships or licenses with third parties.

In addition to reviewing critical IP strategies, this podcast discusses the recent Knopp – Biogen Idec transaction, in which Pepper served as IP counsel. Knopp developed the drug, dexpramipexole, for the treatment of amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s disease, and potentially other indications. In August, Biogen Idec and Knopp Neurosciences entered into an exclusive, worldwide license agreement under which Biogen Idec will develop and commercialize the drug.

Email podcasts@pepperlaw.com to subscribe to Pepper Hamilton’s IP Alerts and Updates.

MP3 File

Data protection laws have changed, so we have revised our Privacy Policy.